EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fragment‐Merging Strategies with Known Pyrimidine Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis

Tim Kirkman iD, Suk Fun Tan, Sair Maximo Chavez-Pacheco, Alexander Hammer, Chris Abell, Manuela Tosin, Anthony G Coyne, Marcio V B Dias

ChemMedChem · 2023

DOI: 10.1002/cmdc.202300240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2023. Verfasst von Tim Kirkman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Warwick, Gibbet Hill, Coventry, CV4 7AL, UK. Hauptthemen laut MEDLINE: Tetrahydrofolate Dehydrogenase, Mycobacterium tuberculosis, Pyrimidines, Folic Acid Antagonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EPRSC, DAAD, Cambridge Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dihydrofolate reductase (DHFR) is a key enzyme involved in the folate pathway that has been heavily targeted for the development of therapeutics against cancer and bacterial and protozoa infections amongst others. Despite being an essential enzyme for Mycobacterium tuberculosis ( Mtb ) viability, DHFR remains an underexploited target for tuberculosis (TB) treatment. Herein, we report the preparation and evaluation of a series of compounds against Mtb DHFR ( Mtb DHFR). The compounds have been designed using a merging strategy of traditional pyrimidine‐based antifolates with a previously discovered unique fragment hit against Mtb DHFR. In this series, four compounds displayed a high affinity against Mtb DHFR, with sub‐micromolar affinities. Additionally, we determined the binding mode of six of the best compounds using protein crystallography, which revealed occupation of an underutilised region of the active site.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tetrahydrofolate DehydrogenaseMycobacterium tuberculosisPyrimidinesFolic Acid AntagonistsAntitubercular AgentsStructure-Activity RelationshipMolecular StructureCrystallography, X-RayDose-Response Relationship, DrugMicrobial Sensitivity TestsHumansCatalytic Domain

Stichwörter der Autor:innen

crystallographydihydrofolate reductasefragment-based drug discoverytuberculosis

Substanzen

Tetrahydrofolate DehydrogenasePyrimidinesFolic Acid AntagonistsAntitubercular Agents

Autor:innen und Institutionen

  • Department of Chemistry, University of Warwick, Gibbet Hill, Coventry, CV4 7AL, UK.
  • Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
  • Department of Microbiology, Institute of Biomedical Science, University of São Paulo, Av. Prof. Lineu Prestes 1374, CEP 05508-000, São Paulo, Brazil.

ORCID-Profile: Tim Kirkman

Förderung

  • EPRSC
  • DAAD
  • Cambridge Trust
  • Emmanuel College, Cambridge
  • Ministry of Education, Malaysia
  • FAPESP
  • University of Warwick
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Kirkman, T., Fun Tan, S., Chavez-Pacheco, S. M., Hammer, A., Abell, C., Tosin, M., Coyne, A. G., & Dias, M. V. B. (2023). Fragment‐Merging Strategies with Known Pyrimidine Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis. ChemMedChem. https://doi.org/10.1002/cmdc.202300240

Vancouver

Kirkman T, Fun Tan S, Chavez-Pacheco SM, Hammer A, Abell C, Tosin M, et al. Fragment‐Merging Strategies with Known Pyrimidine Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis. ChemMedChem. 2023. doi:10.1002/cmdc.202300240

BibTeX
@article{Kirkman2023,
  author = {Kirkman, Tim and Fun Tan, Suk and Chavez-Pacheco, Sair Maximo and Hammer, Alexander and Abell, Chris and Tosin, Manuela and Coyne, Anthony G and Dias, Marcio V B},
  title = {Fragment‐Merging Strategies with Known Pyrimidine Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis},
  journal = {ChemMedChem},
  year = {2023},
  doi = {10.1002/cmdc.202300240}
}
Kostenlos starten →